Skip to main content

COVID-19 Topic Center

HEOR News

News
For nusinersen to be cost-effective without newborn screening for infantile-onset spinal muscular atrophy, the cost of the drug would need to be reduced substantially, according to a study published in The Journal of Pediatrics.  “Universal newborn screening for spinal muscular atrophy provides…
News
No biologic strategies in treatment guidelines for ankylosing spondylitis were cost-effective at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year (QALY), according to a study published in the Journal of Managed Care & Specialty Pharmacy.  “Nevertheless,” researchers…
News
For detecting occult atrial fibrillation in patients with cryptogenic stroke, 3-year implantable loop recorder monitoring has a cost per quality-adjusted life-year (QALY) gained in the range of other publicly funded therapies, according to a study published online in the International Journal of…
News
Preemptive pharmacogenomic panel testing is cost-effective for cardiovascular disease management for a population 45 to 64 years old at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year (QALY), according to a study published online in Genetics in Medicine.  “Given its…
News
The immunotherapy drug tisagenlecleucel is associated with an “exceedingly high” incremental cost-effectiveness ratio for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who failed two or more lines of systemic therapies, according to a cost utility analysis that took a…
Conference Insider
When compared to prostaglandin analogs (PGA), latanoprostene bunod appears to be cost-saving in the treatment of primary open-angle glaucoma, according to data presented at AMCP Nexus 2019.  According to the study, “Latanoprostene bunod is a nitric oxide donating PGA that lowers intraocular…
News Connection
According to a recent study, despite numerous effective treatments for asthma, a significant faction of patients do not achieve sustained asthma control and could be faced with increased financial burden and decreased quality-adjusted life years (QALY).  J Mark FitzGerald, MD, professor in the…
Conference Insider
A team of researchers from The Institute for Clinical and Economic Review (ICER) recently examined the cost-effectiveness and value for use of the extended-release partial opioid agonist, CAM2038, among patients with opioid use disorder (OUD). Varun Kumar, MPH, MSc, associate director of health…
Conference Insider
During a session held at the ISPOR annual meeting, Jack Sheehan, PhD, MBA, discussed health care utilization and associated costs among patients with treatment-resistant depression (TRD) who are covered by commercial health plans, Medicaid, and Medicare.  At the start of the session Dr Sheehan…
Conference Insider
Monthly health care costs more than triple after patients with nonalcoholic fatty liver disease (NAFLD) and its more advanced form, nonalcoholic steatohepatitis (NASH), receive a diagnosis of cirrhosis, according to a study presented during a poster session at ISPOR 2019.  “Identifying patients…
Back to Top